Miami Jewish Health

Enrolling Clinical Trials
Marc E Agronin, MD, Principal Investigator

Name of Study: BOEHRINGER-INGELHEIM 1346.23
Description of Study: This is a Phase II study to investigate efficacy and safety of different doses of orally administered BI 425809 compared to placebo in treatment of cognitive impairment due to Alzheimer's disease.
Indication: Mild to Moderate Alzheimer's Disease
Recruiting Participant Age: 55+
Duration of Study: approximately 7 months (12-week treatment period)

Name of Study: EISAI Delphia 201
Description of Study: This is a Phase II study evaluating the safety, tolerability and efficacy of E2027 in subjects with Dementia with Lewy Bodies.
Indication: Meets criteria for probable Dementia with Lewy Bodies Alzheimer's Disease
Recruiting Participant Age: 50 - 85
Duration of Study: 22 weeks

Name of Study- MIND Study- Long-Term Nicotine Treatment of Mild Cognitive Impairment. Academia Study, Funded by the National Institute on Aging (NIA) and conducted by Vanderbilt University and University of Southern California
Description of Study: The purpose of the Memory Improvement through Nicotine Dosing (MIND) phase II study, is to determine whether nicotine (in patch form) improves memory and functioning in adults diagnosed with MCI
Indication: Mild Cognitive Impairment or Memory Loss
Recruiting Participant Age: 55years +
Duration of Study: 2 years

Name of Study: Longeveron
Description of Study: This is a Phase I study to evaluate the safety and potential efficacy of Longeveron Allogenic Human Mesenchymal Stem Cell (LMSC) Infusion versus placebo in patients with Alzheimer's disease.
Indication: Mild Alzheimer's Disease
Recruiting Participant Age: 55 - 80
Duration of Study: 52 weeks after infusion with LMSCs

Name of Study: Neurotrope NTRP 101-203
Description of Study: This is a Phase II study assessing the safety, tolerability and efficacy of Bryostatin in treatment of moderately severe to severe Alzheimer's Disease in subjects not receiving Memantine treatment.
Indication: Moderately Severe to Severe Alzheimer's Disease
Recruiting Participant Age: 55 - 85
Duration of Study: approximately 7 months (12-week treatment period)

Name of Study: Eli Lilly (TrailBlazer-ALZ) 15T-MC-AACG(b)
Description of Study: This is a Phase II, double blinded study, evaluating the safety, tolerability and efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Indication: Early Alzheimer's Disease/Progressive Cognitive changes > 6 months
Recruiting Participant Age: 60 - 85
Duration of Study: approximately 18 months.

Name of Study: S-CitAD – Johns Hopkins
Description of Study: This is a Phase II placebo-controlled, masked, study assessing the safety, tolerability and efficacy of Escitalopram for Agitation in Alzheimer's Disease.in subjects not receiving Memantine treatment.
Indication: Alzheimer's Disease with Agitation
Recruiting Participant Age: 18 years +
Duration of Study: approximately 24 weeks (12-week treatment period)

If you are interested in participating or learning more about our clinical trials, please call 305.514.8710 or send an email to :

EDiaz1@miamijewishhealth.org

RCastaneda@miamijewishhealth.org

January 2019